Table 2.
Sensitivity and specificity of all three programs at a threshold of 10 and 20%
| Threshold | BRCAPRO | BOADICEA | Myriad |
|---|---|---|---|
| Mutation carrier, N = 48 | |||
| Sensitivity % (95% CI) | |||
| 10 | 85 (72–94) | 85 (72–94) | 88 (75–95) |
| 20 | 81 (67–91) | 81 (67–91) | 48 (33–63) |
| Average of calculated risk | 61.8 (52–72) | 57.9 (48–68) | 28.6 (22–35) |
| Correlation to | |||
| BRCAPRO | 1 | ||
| BOADICEA | 0.93 (0.88–0.96) | 1 | |
| Myriad | 0.56 (0.33–0.73) | 0.65 (0.45–0.79) | 1 |
| Inter-method agreement (kappa) at threshold 10% | |||
| BRCAPRO | 1 | ||
| BOADICEA | 83% (61–100%) | 1 | |
| Myriad | 56% (21–90%) | 56% (21–90%) | 1 |
| Mutation non-carrier, N = 135 | |||
| Specificity % (95% CI) | |||
| 10 | 62 (53–70) | 56 (47–64) | 67 (59–75) |
| 20 | 72 (63–79) | 70 (61–77) | 94 (89–97) |
| Average of calculated risk | 17.3 (14–21) | 17.8 (14–21) | 9.5 (8–11) |
| Correlation to | |||
| BRCAPRO | 1 | ||
| BOADICEA | 0.81 (0.74–0.86) | 1 | |
| Myriad | 0.42 (0.27–0.55) | 0.32 (0.16–0.46) | 1 |
| Inter-method agreement (kappa) at threshold 10% | |||
| BRCAPRO | 1 | ||
| BOADICEA | 74% (63–86%) | 1 | |
| Myriad | 34% (17–50%) | 26% (10–42%) | 1 |